Chemomab shareholders approve CEO Dale Pfost as Chairman of the Board

Chemomab Therapeutics Ltd.

Special meeting on Feb 10, 2022; 89,749,560 shares represented (~39.35% of outstanding).
Shareholders voted to approve CEO Dr. Dale Pfost as Chairman of the Board.
Vote results: 84,227,920 FOR, 5,510,320 AGAINST, 11,320 ABSTAIN.
Requisite majority under Israeli Companies Law satisfied; non-controlling shareholder votes also approved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.